JP2022500423A5 - - Google Patents
Info
- Publication number
- JP2022500423A5 JP2022500423A5 JP2021513996A JP2021513996A JP2022500423A5 JP 2022500423 A5 JP2022500423 A5 JP 2022500423A5 JP 2021513996 A JP2021513996 A JP 2021513996A JP 2021513996 A JP2021513996 A JP 2021513996A JP 2022500423 A5 JP2022500423 A5 JP 2022500423A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutical compositions
- compositions according
- therapeutic agent
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730837P | 2018-09-13 | 2018-09-13 | |
| US62/730,837 | 2018-09-13 | ||
| PCT/IB2019/001035 WO2020053664A1 (en) | 2018-09-13 | 2019-09-13 | Combination therapy for the treatment of estrogen-receptor positive breast cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500423A JP2022500423A (ja) | 2022-01-04 |
| JP2022500423A5 true JP2022500423A5 (cg-RX-API-DMAC7.html) | 2022-09-22 |
| JP7441213B2 JP7441213B2 (ja) | 2024-02-29 |
Family
ID=69777646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513996A Active JP7441213B2 (ja) | 2018-09-13 | 2019-09-13 | エストロゲン受容体陽性乳癌の治療のための併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220047563A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3849550B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7441213B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112912078B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3110788A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2993363T3 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI841598B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020053664A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI882964B (zh) | 2018-09-13 | 2025-05-11 | 大陸商恒翼生物醫藥(上海)股份有限公司 | Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014009303A (es) * | 2012-01-31 | 2014-10-14 | Novartis Ag | Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer. |
| WO2014128655A1 (en) * | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
| KR102307566B1 (ko) * | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
| BR122019007990B1 (pt) * | 2013-11-18 | 2021-05-04 | Forma Therapeutics, Inc | Composto, e, composição farmacêutica |
| WO2016203335A1 (en) * | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| WO2017015027A1 (en) * | 2015-07-20 | 2017-01-26 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2018097977A1 (en) * | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| US20180153867A1 (en) * | 2016-12-06 | 2018-06-07 | Gilead Sciences, Inc. | Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| US20180153868A1 (en) * | 2016-12-06 | 2018-06-07 | Gilead Sciences, Inc. | Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| EP3758753A1 (en) * | 2018-02-27 | 2021-01-06 | Pfizer Inc | Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor |
-
2019
- 2019-09-12 TW TW108133098A patent/TWI841598B/zh active
- 2019-09-13 CN CN201980059916.5A patent/CN112912078B/zh active Active
- 2019-09-13 WO PCT/IB2019/001035 patent/WO2020053664A1/en not_active Ceased
- 2019-09-13 JP JP2021513996A patent/JP7441213B2/ja active Active
- 2019-09-13 ES ES19861171T patent/ES2993363T3/es active Active
- 2019-09-13 EP EP19861171.7A patent/EP3849550B1/en active Active
- 2019-09-13 US US17/275,462 patent/US20220047563A1/en not_active Abandoned
- 2019-09-13 CA CA3110788A patent/CA3110788A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002886A (es) | Terapia de combinacion para el tratamiento de cancer de mama triple negativo. | |
| JP2024507938A5 (cg-RX-API-DMAC7.html) | ||
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| JP2014512356A5 (cg-RX-API-DMAC7.html) | ||
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| JP2016528162A (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| JP2016528162A5 (cg-RX-API-DMAC7.html) | ||
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| JP2019526595A5 (cg-RX-API-DMAC7.html) | ||
| JP2024516795A5 (cg-RX-API-DMAC7.html) | ||
| JP2024516363A5 (cg-RX-API-DMAC7.html) | ||
| MX2013008673A (es) | Derivados del tipo del azaindazol o diazaindazol como medicamento. | |
| JP2015528501A5 (cg-RX-API-DMAC7.html) | ||
| JP2020523354A5 (cg-RX-API-DMAC7.html) | ||
| RU2015155283A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| TN2012000493A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| JP2009506054A5 (cg-RX-API-DMAC7.html) | ||
| JP2006500346A5 (cg-RX-API-DMAC7.html) | ||
| WO2013071056A3 (en) | Combination drug therapy for the treatment of solid tumors | |
| JP2014512355A5 (cg-RX-API-DMAC7.html) | ||
| RU2017128616A (ru) | Комбинированное лекарственное средство | |
| JP2013511526A5 (cg-RX-API-DMAC7.html) | ||
| JP2017507151A5 (cg-RX-API-DMAC7.html) | ||
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| JP2022500431A5 (cg-RX-API-DMAC7.html) |